--- title: "Enveric reports second quarter 2026 net loss of $3.0 million" url: "https://aibio.space/news/enveric-reports-second-quarter-2026-net-loss-3-0-million/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-14" section: "Company Updates" tickers: "NASDAQ:ENVB" source: "https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/ex99-1.htm" summary: "The company reported cash-on-hand of $8.3 million as of June 30, 2026, and an update on its lead candidate EB-003 ahead of an IND submission." --- By the aibio.space news desk. Sources - [Enveric Biosciences 8-K, Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/ex99-1.htm) - [Enveric Biosciences, Inc. 10-K (2026-03-27): business](https://www.sec.gov/Archives/edgar/data/890821/000149315226013294/form10-k.htm) - [Enveric Biosciences, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/890821/000149315226013294/) [ENVB](https://aibio.space/companies/enveric-biosciences/) 2026-08-14 # Enveric reports second quarter 2026 net loss of $3.0 million Tickers [ENVB](https://aibio.space/companies/enveric-biosciences/) The company reported cash-on-hand of $8.3 million as of June 30, 2026, and an update on its lead candidate EB-003 ahead of an IND submission. ## Key facts - **Company**: Enveric Biosciences, Inc. (NASDAQ: ENVB) - **News type**: Company Updates - **Primary source**: [Enveric Biosciences 8-K, Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/ex99-1.htm) *Old laboratory glassware in a display case. Photo: LukaszKatlewa, CC BY 4.0, via Wikimedia Commons. The picture shows the field, not the companies named.* Enveric Biosciences, Inc. reported financial results for the second quarter ended June 30, 2026, in an earnings release furnished with a Form 8-K dated August 14, 2026. The company reported a net loss attributable to stockholders of $3.0 million for the quarter and said it had cash-on-hand of $8.3 million as of June 30, 2026. The release also updated investors on EB-003, the lead candidate in its EVM301 Series. ## Second quarter results Net loss attributable to stockholders was $3.0 million for the quarter, including $0.3 million in net non-cash expense. The basic and diluted loss per share was $0.76. For the quarter ended June 30, 2025, the company reported a net loss of $2.5 million, including $0.5 million in net non-cash expense, and a basic and diluted loss per share of $11.65. For the quarter ended June 30, 2026, the company raised gross proceeds of $5.0 million through offerings and $1.5 million from the exercise of warrants. The release does not state a cash runway in months. ## Development of EB-003 The release says the company is continuing IND-enabling studies for EB-003. It reported GloSensor cAMP assay data showing that EB-003 consistently exhibited a differentiated non-hallucinogenic profile, which complements previously reported BRET assay findings. The company also announced in vitro results showing that EB-003 did not exhibit photoreactive potential. All of these results are preclinical and in vitro. The release reports no human data for EB-003, and words such as promising and encouraging are the company's own. The company has started genotoxicity studies, which the release describes as an important component of the preclinical safety package required to support submission of an IND application. Joseph Tucker, Ph.D., Chief Executive Officer, said: "The second quarter was highlighted by important progress across the key activities supporting our planned first-in-human clinical trial of EB-003." ## Intellectual property and financing The company said it secured a new U.S. patent covering methods of treating psychiatric disorders using compounds from its EVM301 Series, identified in the release as U.S. Patent No. 12,605,361. It also received a Notice of Allowance from the USPTO for a patent application covering its EVM401 Series. During the quarter, the company closed a private placement, priced at-the-market under Nasdaq rules, for approximately $5.0 million in upfront gross proceeds. The release says the placement could bring up to approximately $8.9 million more if the associated warrants are exercised in full. ## The company and its lead program The company's annual report on Form 10-K, filed March 27, 2026, describes Enveric as a biotechnology company focused on next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB-003, is described as the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors. EB-003 is a novel derivative of N,N-Dimethyltryptamine, known as DMT, and is advancing through preclinical studies toward first-in-human studies. The company was incorporated in Delaware in February 1994 as Spatializer Audio Laboratories, Inc. ## Recent financial data The XBRL data that accompanies the company's filings states the following figures from the annual report. For the fiscal year ended December 31, 2025, research and development expense was $2.8 million, net income (loss) was negative $8.8 million, and cash from operations was negative $8.1 million. For the fiscal year ended December 31, 2024, research and development expense was $2.8 million, net income (loss) was negative $9.6 million, and cash from operations was negative $7.7 million. ## The risks ahead Enveric still has to finish its IND-enabling studies, submit the IND application and move EB-003 into a first-in-human trial. Those are the priorities the CEO set for the second half of 2026, and the text gives no date for either the filing or the trial. The company reported a net loss in the quarter and cash-on-hand of $8.3 million, while cash from operations was negative $8.1 million for 2025. The release does not state a cash runway. Part of its funding depends on warrants: up to approximately $8.9 million more arrives only if the associated warrants are exercised in full. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ENVB Enveric Biosciences, Inc. NASDAQ ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/enveric-reports-second-quarter-2026-net-loss-3-0-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Enveric reports second quarter 2026 net loss of $3.0 million", 2026-08-14, https://aibio.space/news/enveric-reports-second-quarter-2026-net-loss-3-0-million/